Elbion Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
47
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$18M
Elbion General Information
Description
Provider of pharmaceutical research and development services. The company operates as a specialty pharmaceutical company focused on the development and commercialization of therapeutics for neurological diseases and immunological disorders.
Contact Information
Website
pharmapark-radebeul.deCorporate Office
- Meissner Straße 191
- 01445 Radebeul
- Germany
Corporate Office
- Meissner Straße 191
- 01445 Radebeul
- Germany
Elbion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 14-Nov-2008 | $18M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 10-Jul-2005 | Completed | Generating Revenue |
Elbion Patents
Elbion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20090143367-A1 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | Active | 30-Nov-2007 | ||
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | Inactive | 30-Nov-2007 | ||
| AU-2008329072-A1 | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 | Inactive | 30-Nov-2007 | ||
| CA-2706986-A1 | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 | Inactive | 30-Nov-2007 | ||
| EP-2227472-A1 | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 | Inactive | 30-Nov-2007 | C07D487/04 |
Elbion Signals
Elbion Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | ||
| BayTech Venture Capital | Venture Capital | Minority | ||
| Burrill & Co | Merchant Banking Firm | Minority | ||
| Deutsche Venture Capital | Corporate Venture Capital | Minority | ||
| Idinvest Partners | PE/Buyout | Minority |
Elbion Investments & Acquisitions (2)
Elbion’s most recent deal was a Corporate Asset Purchase with DrugAbuse Sciences (Late-Stage Drug Candidate and Product Rights). The deal was made on 19-Jan-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DrugAbuse Sciences (Late-Stage Drug Candidate and Product Rights) | 19-Jan-2007 | Corporate Asset Purchase | Buildings and Property | ||
| 4 AZA Bioscience | 12-Aug-2006 | Merger/Acquisition | Drug Discovery |
Elbion FAQs
-
When was Elbion founded?
Elbion was founded in 2002.
-
Where is Elbion headquartered?
Elbion is headquartered in Radebeul, Germany.
-
What is the size of Elbion?
Elbion has 47 total employees.
-
What industry is Elbion in?
Elbion’s primary industry is Drug Delivery.
-
Is Elbion a private or public company?
Elbion is a Private company.
-
What is the current valuation of Elbion?
The current valuation of Elbion is .
-
What is Elbion’s current revenue?
The current revenue for Elbion is .
-
How much funding has Elbion raised over time?
Elbion has raised $42.2M.
-
Who are Elbion’s investors?
3i Group, BayTech Venture Capital, Burrill & Co, Deutsche Venture Capital, and Idinvest Partners are 5 of 10 investors who have invested in Elbion.
-
When was Elbion acquired?
Elbion was acquired on 14-Nov-2008.
-
Who acquired Elbion?
Elbion was acquired by Biotie Therapies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process